The coxibs are a subset of non-steroidal anti-inflammatory drugs (NSAIDs) that primarily target cyclooxygenase-2 (COX-2) to inhibit prostaglandin signaling and reduce inflammation. However, mechanisms to inhibit other members of the prostaglandin signaling pathway may improve selectivity and reduce off-target toxicity. Here, we report a novel binding site for celecoxib on prostaglandin E synthase (PTGES), an enzyme downstream of COX-2 in the prostaglandin signaling pathway, using a cleavable chelation-assisted biotin probe 6. Evaluation of the multifunctional probe 6 revealed significantly improved tagging efficiencies attributable to the embedded picolyl functional group. Application of the probe 6 within the small molecule interactome mapping by photo-affinity labeling (SIM-PAL) platform using photo-celecoxib as a reporter for celecoxib identified PTGES and other membrane proteins in the top eight enriched proteins from A549 cells. Carbonic anhydrase 12, a known protein target of celecoxib, was also enriched. Four binding sites to photo-celecoxib were additionally mapped by the probe 6, including a binding site with PTGES. The binding interaction with PTGES was validated by competitive displacement with celecoxib and known PTGES inhibitor licofelone. The binding site of photo-celecoxib on PTGES enabled the development of a structural model of the interaction and will inform the design of new selective inhibitors of the prostaglandin signaling pathway.
Main textInflammation is a major immune response to injury or infection that leads to short-term symptoms of swelling and pain and, when dysregulated, long-term diseases including arthritis, autoimmune disorders, and neurodegeneration. Induction of the acute inflammatory response is primarily mediated by prostaglandin signaling. 1 The prostaglandins are produced by the cyclooxygenases COX-1 and COX-2, which transform arachidonic acid into prostaglandin H2 (PGH2) for further tailoring by prostaglandin synthases ( Figure 1A). The specific inhibition of prostaglandin E2 (PGE2) production and signaling has been an anti-inflammatory target since the development of the first non-steroidal anti-inflammatory drug (NSAID), aspirin, and the subsequent introduction of selective COX-2 inhibitors known as the "coxibs". 2 While therapeutic inhibition of COX-1 and COX-2 is associated with gastrointestinal toxicity, the selective COX-2 inhibitor rofecoxib was withdrawn due to cardiovascular toxicity. 3 This cardiovascular toxicity may arise from the simultaneous suppression of PGE2 and the cardiovascular protectant PGI2 by selective COX-2 inhibitors. 4 As a result, identification of PGE2-selective inhibitors by targeting the inducible prostaglandin E synthase (PTGES) has been the focus of several efforts. 5-8 Here, we report the discovery of a direct interaction between PTGES and celecoxib using binding site hotspot mapping with an isotopically-coded cleavable chelation-assisted biotin probe (CBPA, 6).Chemical proteomics methods have enabled the unbiased identification of protein...